Replies to post #89785 on Innovation Pharmaceuticals Inc (IPIX)

[JUST 10-11-12]

nice

[BooDog]

Nice George. I think the presentation is an EXCELLENT move. Cellceutix could get a bite right away from this. Also to get nibbles moving into the EU with yet another well established university hospital for trials. Right away. Defined in the bio sector in terms of a few months imo. lol But it's a great place to be with such a strong drug candidate. Get our feet wet with the European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP) and the European Commission (EC). Not all at once of course, it'll be a process that takes time but it will be exciting times. Welcome to Copenhagen. Welcome Cellceutix to the 2015/2016 Biotech Olympics. :-)

Okay, good coffee this morning.

“A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)” will be given in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Copenhagen, Denmark from April 25-28, 2015. ECCMID is one of the largest annual gatherings of infectious disease experts in the world, and an ideal forum to present the results of a clinical trial. Dr. Daniel Jorgensen, Cellceutix’s Chief Medical Officer, will give the presentation during a session entitled “New Antibacterial Agents – Phase 2 and Phase 3 Clinical Trials.”

...
In addition to the clinical data from the ABSSSI trial, Cellceutix will also present important preclinical data. The abstract entitled Synthetic Novel Host Defense Protein Mimetics for the Treatment of Gram-Negative Bacterial Infections has been accepted for oral presentation in the session entitled Drug Discovery. “This is an opportunity for experts to hear about the other promising defensin-mimetics — not just Brilacidin,” said Dr. Jorgensen. ”These compounds have potential to treat serious Gram-negative infections, including those identified by CDC as ‘antibiotic resistance threats.’ “

The final presentation, a poster entitled Brilacidin, Host Defense Peptide Mimetic, One of a New Class of Immunomodulatory Agents that can Target Multiple Disease Indications, will be given in the category of New Antimicrobials. “This is an important poster, as it highlights the immunomodulatory properties of Brilacidin, in addition to its antimicrobial properties,” Dr. Jorgensen added. “These animal data support the use of topical Brilacidin in humans to prevent or ameliorate oral mucositis, a painful condition in cancer patients undergoing chemoradiation therapy. A phase 2 clinical trial is about to begin.”

george h Thursday, 01/29/15 09:10:09 PM
Re: BooDog post# 89784
Post # of 89812

I just posted to SA:
Thanks Karin; nice piece.
You didn't want to mention it but I will: there will be a presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Copenhagen, Denmark from April 25-28, 2015. ECCMID is one of the largest annual gatherings of infectious disease experts in the world, and an ideal forum to present the results of a clinical trial.
This will be the first presentation to a MEDICAL audience to report on the recently completed phase 2b clinical trial of Brilacidin. There should be lots of new eyes of people with insight and money to invest. Shorts beware!
gcharvey